{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:28:03Z","timestamp":1790756883318,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ajo.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:23:53Z","timestamp":1781076233000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Antiadalimumab Antibodies in Patients With Inflammatory Ocular Diseases: Incidence and Clinical Outcomes"],"prefix":"10.1016","volume":"290","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1053-8651","authenticated-orcid":false,"given":"Paulina","family":"Liberman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9408-2972","authenticated-orcid":false,"given":"Sophia E.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7665-0964","authenticated-orcid":false,"given":"Israel J.","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia M.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7517-7706","authenticated-orcid":false,"given":"Meghan K.","family":"Berkenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn M.","family":"Burkholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3509-5770","authenticated-orcid":false,"given":"Jennifer E.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Jabs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2026.06.003_bib0001","unstructured":"U.S. Food and Drug Administration. HUMIRA (adalimumab) injection, solution for subcutaneous use: prescribing information. 2011. Accessed December 1, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125057s399lbl.pdf"},{"issue":"10","key":"10.1016\/j.ajo.2026.06.003_bib0002","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"10050","key":"10.1016\/j.ajo.2026.06.003_bib0003","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ajo.2026.06.003_bib0004","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2026.06.003_bib0005","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ophtha.2025.10.004","article-title":"Adalimumab versus conventional immunosuppression for uveitis (ADVISE) trial","volume":"133","author":"Jabs","year":"2026","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2026.06.003_bib0006","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.ophtha.2016.08.025","article-title":"Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies","volume":"123","author":"Cordero-Coma","year":"2016","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2026.06.003_bib0007","first-page":"1043","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis","volume":"35","author":"Leinonen","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ajo.2026.06.003_bib0008","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/archdischild-2018-315060","article-title":"Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis","volume":"104","author":"Skrabl-Baumgartner","year":"2019","journal-title":"Arch Dis Child"},{"issue":"2","key":"10.1016\/j.ajo.2026.06.003_bib0009","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10067-019-04798-6","article-title":"Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching","volume":"39","author":"Brunelli","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.ajo.2026.06.003_bib0010","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bjophthalmol-2021-319072","article-title":"Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study","volume":"106","author":"Sejournet","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.06.003_bib0011","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajo.2022.03.017","article-title":"Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy","volume":"240","author":"Eurelings","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"7-8","key":"10.1016\/j.ajo.2026.06.003_bib0012","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/09273948.2021.1936565","article-title":"Anti-adalimumab antibodies in patients with non-infectious ocular inflammatory disease: a case Series","volume":"30","author":"McKay","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.ajo.2026.06.003_bib0013","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jamaophthalmol.2022.5584","article-title":"Antidrug antibodies to tumor necrosis factor \u03b1 inhibitors in patients with noninfectious uveitis","volume":"141","author":"Bellur","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2026.06.003_bib0014","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajo.2024.09.008","article-title":"Adalimumab drug monitoring and treatment adjustment to drug antibodies in noninfectious uveitis","volume":"268","author":"Pichi","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2026.06.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e29313","article-title":"Risk factors for development of anti-adalimumab antibodies in non-infectious uveitis","volume":"10","author":"Bromeo","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.003_bib0016","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1186\/s12967-025-07352-y","article-title":"Immunogenicity of adalimumab in patients with noninfectious uveitis based on therapeutic drug monitoring","volume":"23","author":"Han","year":"2025","journal-title":"J Transl Med"},{"issue":"9","key":"10.1016\/j.ajo.2026.06.003_bib0017","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/ceo.14175","article-title":"The standardisation of uveitis nomenclature (SUN) project","volume":"50","author":"Jabs","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.06.003_bib0018","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2026.06.003_bib0019","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41395-018-0073-0","article-title":"Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the POETIC study","volume":"113","author":"Ungar","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.ajo.2026.06.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254548","article-title":"Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory Bowel disease","volume":"16","author":"Kato","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ajo.2026.06.003_bib0021","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/rheumatology\/keac564","article-title":"Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis","volume":"62","author":"Hum","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.003_bib0022","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/epirev\/mxac001","article-title":"The conundrum of clinical trials for the uveitides: appropriate outcome measures for one treatment used in several diseases","volume":"44","author":"Jabs","year":"2022","journal-title":"Epidemiol Rev"},{"issue":"8","key":"10.1016\/j.ajo.2026.06.003_bib0023","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/09273948.2023.2256850","article-title":"Immunogenicity of adalimumab in patients with non-infectious uveitis: systematic review and meta-analysis","volume":"32","author":"Pach\u00f3n-Su\u00e1rez","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"issue":"7-8","key":"10.1016\/j.ajo.2026.06.003_bib0024","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1080\/09273948.2020.1749857","article-title":"Escalation to weekly adalimumab for the treatment of ocular inflammation","volume":"29","author":"Liberman","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"10.1016\/j.ajo.2026.06.003_bib0025","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ophtha.2020.04.009","article-title":"Success of weekly adalimumab in refractory ocular inflammatory disease","volume":"127","author":"Lee","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.06.003_bib0026","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ajo.2024.12.009","article-title":"High body mass index is associated with lower adalimumab serum levels and higher disease activity in noninfectious uveitis","volume":"271","author":"Pichi","year":"2025","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426003053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426003053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:31:50Z","timestamp":1788280310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426003053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"alternative-id":["S0002939426003053"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.06.003","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiadalimumab Antibodies in Patients With Inflammatory Ocular Diseases: Incidence and Clinical Outcomes","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}